Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,500 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Follow-Up Questions
¿Quién es el CEO de Bausch + Lomb Corp?
Mr. Brenton Saunders es el Chairman of the Board de Bausch + Lomb Corp, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción BLCO?
El precio actual de BLCO es de $15.13, ha decreased un 1.62% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Bausch + Lomb Corp?
Bausch + Lomb Corp pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Bausch + Lomb Corp?
La capitalización bursátil actual de Bausch + Lomb Corp es $5.3B
¿Es Bausch + Lomb Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 15 analistas han realizado calificaciones de análisis para Bausch + Lomb Corp, incluyendo 3 fuerte compra, 7 compra, 8 mantener, 1 venta, y 3 fuerte venta
